fiona_glasgow said:Denials are usually procedural rather than clinical, and the order that works reflects that.
fiona_glasgow said:...my insurance denied cost and coverage coverage because...
Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:
- Document medical necessity (BMI, comorbidities, failed alternatives)
- Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
- Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
- Request peer-to-peer review between your doctor and the plan's medical director
- File external appeal with your state insurance department if internal appeal fails
Don't accept the first denial. The appeal process exists for a reason.
bri_stats said:fiona_glasgow said: ...my insurance denied cost and coverage coverage because...
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsClosing the loop on my own question.
Follow-up — getting the denial reason in writing was the step that mattered. It named the criterion, and the criterion was a document I already had.
PedsEndoPhilly said:My insurance denied my PA related to cost and coverage.
PedsEndoPhilly said:...compounded vs brand cost and coverage...
This debate comes up weekly and I think both sides have valid points:
Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable
Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility
My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.